Subscribe
shutterstock_1625917948_nitpicker
nitpicker / Shutterstock.com
11 October 2021Big Pharma

English High Court finds Bayer patent obvious in win for Teva

The English High Court has found that a challenged claim of Bayer's targeted cancer drug sorafenib is invalid due to obviousness, in a win for Israeli pharmaceutical company Teva Pharmaceuticals.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Fed Circ panel reviews $235m GSK award over ‘skinny’ Teva generic
25 February 2021   A panel of the US Court of Appeals for the Federal Circuit has considered for a second time the $235 million award to GlaxoSmithKline after Teva Pharmaceuticals was found to have infringed its Coreg heart drug.
Americas
Biogen sues Teva over MS generic
18 March 2021   A proposed Teva Pharmaceutical generic drug to treat multiple sclerosis infringes patents relating to Vumerity, according to a lawsuit filed by Biogen and Alkermes.
Plant Varieties
Rival sues Monsanto, Bayer over GM plant tech
11 August 2022   Firms accused of using GM tech for herbicide-resistant plants | Plaintiff says its patented tech helps farmers to innovate | US District Court for the District of Delaware.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Americas
Fed Circ panel reviews $235m GSK award over ‘skinny’ Teva generic
25 February 2021   A panel of the US Court of Appeals for the Federal Circuit has considered for a second time the $235 million award to GlaxoSmithKline after Teva Pharmaceuticals was found to have infringed its Coreg heart drug.
Americas
Biogen sues Teva over MS generic
18 March 2021   A proposed Teva Pharmaceutical generic drug to treat multiple sclerosis infringes patents relating to Vumerity, according to a lawsuit filed by Biogen and Alkermes.
Plant Varieties
Rival sues Monsanto, Bayer over GM plant tech
11 August 2022   Firms accused of using GM tech for herbicide-resistant plants | Plaintiff says its patented tech helps farmers to innovate | US District Court for the District of Delaware.

More on this story

Americas
Fed Circ panel reviews $235m GSK award over ‘skinny’ Teva generic
25 February 2021   A panel of the US Court of Appeals for the Federal Circuit has considered for a second time the $235 million award to GlaxoSmithKline after Teva Pharmaceuticals was found to have infringed its Coreg heart drug.
Americas
Biogen sues Teva over MS generic
18 March 2021   A proposed Teva Pharmaceutical generic drug to treat multiple sclerosis infringes patents relating to Vumerity, according to a lawsuit filed by Biogen and Alkermes.
Plant Varieties
Rival sues Monsanto, Bayer over GM plant tech
11 August 2022   Firms accused of using GM tech for herbicide-resistant plants | Plaintiff says its patented tech helps farmers to innovate | US District Court for the District of Delaware.

More features

President Trump 2.0: Five major areas to watch
China’s new policies on foreign investment in healthcare and biotech
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug